Member Info for Aldebaran

Davie_b , your question is reasonable given its been over a month since we last heard and median survival time is currently measured in months.

I also think its reasonable to expect Vlad to put on some kind of investor event to update everyone on his latest meetings and answer questions about cohort 1 plus timelines for next steps.

This is a public PLC, not his own private science experiment after all.

And your holding and mine and anyone's is irrelevant. If someone has one share or 1m shares shouldn't matter and nobody's questions or views carry more or less weight due to there holding size.

This is more of a fan page than a informed investor discussion board and it seems most of the sheep outsource there thinking and understanding of things to Haywain. He himself is only human, makes mistakes, suffers with owners bias and cant know everything etc...

I dont think anything you or AI have asked or suggested is unreasonable whatsoever. Good luck to you. Keep thinking for yourself, you'll do well 👍👍

The chart is still a mess though. Moving averages are all out of order and if you look at the chart on any time frame the overwhelming colour is red.

A close above 200dma is positive but it closed right on the 50ma and volume only marginally increased. Getting above 10p would be positive but I suspect the 10p placees will be frantically selling above that level to bank some profits if the price is moving on non material news and they'll buy back cheaper at the next placing.

Sales is what needs to be made and significant ones to start moving this up and flipping the chart in a sustainable way

Oh and I didnt start this question about how patient 1 and 2 are doing, another poster did but dont let facts get in the way of collecting recommendations from the sheep 😉

Archbishop Holmes, why dont you tell me why it is Avacta are so excited about the latest drug Fap exetecan and the fact it has cured. CURED. 19/21 mice of aggressive cancers without causing any side effects.

I'll give you a clue, go look at the pathfinder drug results from the first CLINICAL drug Fap dox and explain to me what the read across is. What is the same about these 2 drugs and what is different. Then tell me what happens when the most potent topoisomerase inhibitor on Earth goes into human carried by the most exquisite delivery vehicle in existence also. Capable of putting 100x more warhead into a tumour than in any healthy tissue.

I think the science will baffle you and you will give up but thats fine. Im here to help should you have any questions. Also, note the TAM for that drug is over £200bn per annum 😉

Ive told you enough now, back to letting you think you're some kind of superior biotech investor who has it all figured out lmao.

Maybe you can answer this basic question about HEMO...

Are patient 1 and 2 still alive and what has their quality of life been like so far. Has the cancer started to come back yet? I won't hold my breath waiting for a response because you're clueless on the stuff that matters.

You probably know less about hemo than you do avacta and that's saying something.

Haywain, we saw the update then but was more than a month ago. All we knew then was they were alive. Great. Are they still? No mention in recent update and would have been so easy for Vlad to include thay so why hasn't he?

What has their quality of life been like and has the cancer returned at all yet?

Latest patient had no detectable cancer cells by standard tests so when will we get the advanced tests?

I think these are legitimate questions and ones which can and should easily be answered by Vlad doing some kind of update. It would stop any FUD in its tracks and send the share price through 1600p easily in my opinion. If he gave favourable answers that is.

Right now, we dont know key in formation and in the absence of fact rumour and fud will spread. Before you know it the next update only gets us back to where we are today in terms of valuation because the price has been allowed to slide.

Hopefully you see my point? Yes its about the science but also about much more. Investor relations, communication etc..

Good angle?

Please dont start that nonsense again. I have 30k sat here. I am invested and want it to do well.

Also, read the full thread. I didnt start this, another poster questioned patient 1 and 2 status asking if they "should be worried"

Its worthwhile debating no? Or do we just assume everything is going great all the time and price only going up in a straight line etc etc..

Things happen in clinical trials its entirely normal. All I'm saying, in answer to Davie_B is that we ought to have an update from Vlad after this conference thing is done.

Let's put to bed any FUD and move on. If me saying that is cause for concern than you really have lost all objectivity here...

Hi Dazpink. A month ago we knew that im just wondering their current status that's all and clearly I'm not the only one...

If both patients are alive then they've both beat median survival = HUGE plus.

If both dead then its mixed and much more data needed.

Just a quick interview with proactive or a webinar would be great and have the added benefit of halting any FUD in its tracks. Anyway, enough on the subject for me. Ive made my thoughts clear

Just 1 infusion thats it

JHFH, perhaps you have more info than we do.

Do you knkw patient 1 remains alive today? Same question about patient 2?

Nobody is spreading nonsense. Davie_B just asked a legitimate question in my mind.

Davie_B, I wouldn't say im anxious just sceptical. For all we know patient 1 and/or 2 is now deceased and we have a mixed bag in terms of efficacy. Patient 3 having no detectable cancer cells is great but by standard testing methods so what happens when they look in detail?

Right now, it all is obtuse and before any deals are made for 100's of millions or billions of dollars you can be sure those with the money want more data and proof. Much more. Which is fine but as investors we need to know.

If the drug is working at this low dose albeit not as well as hoped that too is fine because perhaps it will work better at a higher dose etc..

The point or theme is that we remain in the dark and other companies such as the one that shall not be named are much better at putting out updates and communicating with investors so dont tell me it cant be or isn't done. Its just not done by Vlad as hes head down into the science as usual. Right now he has a company valuation to protect and build upon.

Let's have a webinar with open Q&A and put everyone's minds ease I say.

Pingu777 trying to pretend he hasn't read my posts haha

Ok m8 🤥😉

On 15th August after 3rd patient was dosed we had this " The Company is pleased to report that the first two patients treated with HG-CT-1 remain alive at six months and three months post-treatment, respectively."

Which is encouraging, but why not give an update when reporting the safety results of P3 saying similar? 🤔

Ha fair enough pumpkin.

Why would Vlad be invited to this deal making summit if there was a problem with the patience?

Why WOULDNT Hemo come out and shout from the roof tops about how patient 1 and 2 are doing if indeed their both doing great?

2 questions for and against... point being we just have no idea and that's not really on. Vlad needs to get his ass in front of a camera and update is all as soon as he returns to blighty if he wants to maintain the momentum here and not lose too much ground regarding valuation.

It often pays to air on the side of caution with small caps in my experience

Davie_B yes IMO we should be given an update of patience 1 & 2. In the absence of news the rumour and doubt will spread. Are they STILL alive, has their cancer started to come back yet, why has there quality of life been like etc.. all reasonable questions and why I have been saying on here we need some kind of webinar explainer from Vlad.

Argument is that FDA have approved pediatrics so I take that as a huge positive however this note baffles me

"Treatment of this patient, the final participant in the first adult dose cohort, was made possible after the Company secured special permission from the U.S. Food and Drug Administration (FDA) to proceed under exceptional circumstances."

Why was special permission required for patient 3? Were they perhaps under age, maybe close to a birthday or something or has there been something untoward happen to patient one or 2?

We just dont know and that void of information needs plugging sharpish else SP is going to drop as worry starts to set in. Its just how it is. Hence why I sliced last week. I want to see which way market moves from here and/or what the next bit of news confirms.

I do feel their are a LOT of really silly derampers on here who are clueless and simultaneously a lot that are overly zealous and excitable.

Good point Haywain and yes put on NASDAQ and this is a lot higher. Same can be said for a plethora of UK listed small caps though.

Anyway to next week, im expecting those congress people to start buying or their friends to start buying and price to brake though 16quid or with no news or buying then a bit of a pullback until cohort 2 starts along with pediatrics which should then see 16quid brake and company head towards 3000p

An investor webinar would be fab and keep momentum in the absence of new news. Just a nice short explanation with some meet on the bones as to exactly where we are at this point with a few insights from the conference sprinkled in.

Bearhuntr, get a life mate. No idea who u are but guess ive said something unfavourable about your favourite stock? Tough really, it means its probably shhhh it. Get over it

Thats quite funny. People disregard charts all the time and they ain't always right. Its more about probability.

Woth 180p braking with volume was a buy signal.

Failing at 1600p a few times along with other signs such as bearish rsi divergence is a sell signal.

Brake above 1600p is a buy signal.

Like it or not a lot of people use them, some successfully, others not so. Importantly, news always trumps technicals. Always.

Yes, and with so few shares in circulation as well the re-rate can and is and will be rapid. It'll just wipe its feet on the way up as people naturally profit take thats all. This guy talking about novelty being over and price dropping below £10 is clueless.

At least i deramp properly when I start! 🤪

Agree let it roll.

Celtic, not certificate.

And for the 30 - 50bn guy here:

2.3bn per annum is the revenue expected for HG-CT-1 after all said and done. Apply a 10% chance of success (phase 1 standard) and you get a modern day equivalent value of £230m . That shows HEMO is undervalued massively and even the 10% chance of success is ridiculously conservative given 3/3 patient success so far.

A buyout will come for 2-3x peak sales IMO so around 5 - 7bn. That's enough. Let's not be ramping this unnecessarily to 30 or 50bn as it just puts people off